Long thought of as passive bystanders, glial cells are coming under increasing scrutiny as mediators of inflammatory disease in the nervous system. Now, some drug makers are hoping they can be targeted pharmacologically. Cormac Sheridan reports.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cerebrospinal fluid of chronic osteoarthritic patients induced interleukin-6 release in human glial cell-line T98G
BMC Anesthesiology Open Access 25 March 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tango, F.Y. et al. Proc. Natl. Acad. Sci. USA 102, 5856–5861 (2005).
Kawasaki, Y. et al. Nat. Med. 14, 331–336 (2008).
Mallajosyula, J.K. et al. PLoS ONE 3, e1616 (2008).
Panatier, A. et al. Cell 125, 775–784 (2006).
Vezzani, A. et al. Epilepsia 49 Suppl. 2, 24–32 (2008).
Munoz, L. et al. J. Neuroinflammation 4, 21 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Glial cells on the radar. Nat Biotechnol 27, 114–116 (2009). https://doi.org/10.1038/nbt0209-114
Issue Date:
DOI: https://doi.org/10.1038/nbt0209-114
